Incorporating and Switching to Biosimilars: Tools for Overcoming Barriers to Clinical Use
The use of biologic agents is ideally suited for the treatment of patients with inflammatory bowel disease (IBD). However, the widespread use of biosimilars for these and other non-gastrointestinal inflammatory conditions has been met with hesitation.
This program includes information that will increase healthcare providers understanding of biosimilar concepts, encourage implementation of practical approaches to educate patients and providers on the use of biosimilars as first-line agents or switching a patient to biosimilars and improving the ability of providers to discuss biosimilar options with their patients as part of shared-decision making.
Our expert faculty, including gastroenterologists and a pharmacist, describe their experience with switching from the originator drug to a biosimilar and how this transition was successfully made through focusing on collaboration among multiple stakeholders for buy-in and process standardization.
Gastroenterologists, rheumatologists, pharmacists, primary care physicians, nurse practitioners, and physician assistants
At the conclusion of this activity, participants will be able to (or better able to):
- Compare and contrast biosimilars and their reference agents for use in patients with Inflammatory Bowel Disease (IBD) in order to optimize IBD treatment.
- Identify barriers to biosimilar use in practice, and implement practical strategies to overcome these barriers.
- Describe core actionable strategies to increase uptake of biosimilars in clinical practice.
Eu sem integer vitae justo eget magna fermentum.
Shubha Bhat, PharmD, MS, BCACP
Ambulatory Care Clinical Pharmacy Specialist
Crohn’s and Colitis Program
Boston Medical Center
Dr. Bhat has no relevant financial relationships to disclose.
Francis A. Farraye, MD, MSc
Director, Inflammatory Bowel Disease Center
Section of Gastroenterology and Hepatology
Professor of Medicine
Mayo Clinic Alix School of Medicine
Adjunct Professor of Medicine
Boston University School of Medicine
Dr. Farraye is a consultant for Braintree Laboratories, Bristol Meyer Squibb, GlaxoSmithKline, Janssen Biotech, Inc., and Pfizer Inc. He also is a stockholder and on the advisory board for Innovation Pharmaceuticals and is on the data safety monitoring board for Eli Lilly and Company and Theravance Biopharma.
Alan Moss, MD, FACG, AGAF, FEBG, FRCPI
Director, Crohn’s and Colitis Program
Boston Medical Center
Dr. Moss is a consultant for Janssen Pharmaceuticals, Inc., Seres Therapeutics Inc., and Theravance Biopharma.
CME Project Manager: Michael Burk
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CNE Contact Hours: 1, all of which is eligible for pharmacology credit
The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This is a knowledge-based educational activity. Pharmacists will receive 1.0 contact hour (0.10 ceus) for the educational activity. No partial credit is available. ACPE Universal Activity Number (UAN): 0060-9999-20-021-L01-P.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive MOC points, you MUST pass the post-assessment and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through BUSM’s ACCME Program and Activity Reporting System (PARS). Please allow for 6-8 weeks for your MOC points to appear on your ABIM records.
ABIM/MOC: 1 Medical Knowledge MOC points
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Boston University School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCCBoston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
- 1.00 Participation
Feugiat pretium nibh ipsum consequat nisl vel pretium lectus. Vehicula ipsum a arcu cursus vitae congue mauris rhoncus. Morbi leo urna molestie at elementum. Eget duis at tellus at. Molestie at elementum eu facilisis sed odio morbi quis. Egestas congue quisque egestas diam in arcu cursus euismod. Nunc scelerisque viverra mauris in aliquam sem fringilla ut. Sagittis nisl rhoncus mattis rhoncus urna neque. Viverra maecenas accumsan lacus vel. Purus in massa tempor nec feugiat nisl pretium fusce. Facilisi morbi tempus iaculis urna id. In vitae turpis massa sed elementum. Non tellus orci ac auctor augue mauris augue neque gravida. Diam sit amet nisl suscipit adipiscing bibendum est. Enim sit amet venenatis urna cursus. Velit ut tortor pretium viverra suspendisse potenti. Aliquam ultrices sagittis orci a scelerisque purus semper eget. Nisl purus in mollis nunc sed id. Turpis nunc eget lorem dolor sed viverra ipsum nunc.
Lobortis feugiat vivamus at augue. Id velit ut tortor pretium viverra suspendisse potenti nullam ac. Netus et malesuada fames ac turpis egestas integer eget. Augue ut lectus arcu bibendum at varius vel. Mattis molestie a iaculis at erat pellentesque adipiscing. Vitae semper quis lectus nulla at volutpat diam. Et malesuada fames ac turpis. Eu non diam phasellus vestibulum. Pellentesque elit ullamcorper dignissim cras tincidunt lobortis feugiat. Ligula ullamcorper malesuada proin libero nunc consequat interdum varius. Congue mauris rhoncus aenean vel. Imperdiet dui accumsan sit amet nulla facilisi morbi tempus iaculis. Ultrices vitae auctor eu augue. Egestas maecenas pharetra convallis posuere morbi leo. Faucibus et molestie ac feugiat sed lectus vestibulum. Viverra nam libero justo laoreet sit amet cursus sit. Justo donec enim diam vulputate ut pharetra sit amet.